Autoimmune hemolytic anemia (AIHA) is an autoimmune disorder in which various types of auto-antibodies are directed against red blood cells causing their survival to be shortened and resulting in hemo...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for autoimmune hemolytic anemia is limited primarily due to its rarity, affecting fewer than 10,000 individuals in the U.S. The lack of systematic clinical studies and comprehensive phenotype documentation contributes to the challenges in understanding the full scope of the condition. Additionally, the complexity of autoimmune disorders often leads to overlapping symptoms with other conditions, making characterization difficult.
To navigate your care effectively, seek a hematologist with expertise in autoimmune disorders, particularly those specializing in hemolytic anemias. Engaging with a genetic counselor may also be beneficial, especially considering the autosomal recessive inheritance pattern, as they can provide insights into family planning and genetic testing options. While there are no specific patient organizations identified for AIHA, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable information. Participating in clinical trials may also be an option to consider for accessing new therapies.
Research is ongoing in the field of autoimmune hemolytic anemia, with four orphan drugs currently designated for development. These include a humanized IgG4 monoclonal antibody targeting the complement pathway and a bispecific T cell engager antibody, among others. There are currently 55 active clinical trials exploring various aspects of AIHA treatment and management. For more information on these trials, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=autoimmune%20hemolytic%20anemia.
Actionable guidance for navigating care for autoimmune hemolytic anemia
To navigate your care effectively, seek a hematologist with expertise in autoimmune disorders, particularly those specializing in hemolytic anemias. Engaging with a genetic counselor may also be beneficial, especially considering the autosomal recessive inheritance pattern, as they can provide insights into family planning and genetic testing options. While there are no specific patient organizations identified for AIHA, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable information. Participating in clinical trials may also be an option to consider for accessing new therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for autoimmune hemolytic anemia is limited primarily due to its rarity, affecting fewer than 10,000 individuals in the U.S. The lack of systematic clinical studies and comprehensive phenotype documentation contributes to the challenges in understanding the full scope of the condition. Additionally, the complexity of autoimmune disorders often leads to overlapping symptoms with other conditions, making characterization difficult.
To navigate your care effectively, seek a hematologist with expertise in autoimmune disorders, particularly those specializing in hemolytic anemias. Engaging with a genetic counselor may also be beneficial, especially considering the autosomal recessive inheritance pattern, as they can provide insights into family planning and genetic testing options. While there are no specific patient organizations identified for AIHA, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable information. Participating in clinical trials may also be an option to consider for accessing new therapies.
Research is ongoing in the field of autoimmune hemolytic anemia, with four orphan drugs currently designated for development. These include a humanized IgG4 monoclonal antibody targeting the complement pathway and a bispecific T cell engager antibody, among others. There are currently 55 active clinical trials exploring various aspects of AIHA treatment and management. For more information on these trials, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=autoimmune%20hemolytic%20anemia.
Actionable guidance for navigating care for autoimmune hemolytic anemia
To navigate your care effectively, seek a hematologist with expertise in autoimmune disorders, particularly those specializing in hemolytic anemias. Engaging with a genetic counselor may also be beneficial, especially considering the autosomal recessive inheritance pattern, as they can provide insights into family planning and genetic testing options. While there are no specific patient organizations identified for AIHA, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable information. Participating in clinical trials may also be an option to consider for accessing new therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for autoimmune hemolytic anemia is limited primarily due to its rarity, affecting fewer than 10,000 individuals in the U.S. The lack of systematic clinical studies and comprehensive phenotype documentation contributes to the challenges in understanding the full scope of the condition. Additionally, the complexity of autoimmune disorders often leads to overlapping symptoms with other conditions, making characterization difficult.
To navigate your care effectively, seek a hematologist with expertise in autoimmune disorders, particularly those specializing in hemolytic anemias. Engaging with a genetic counselor may also be beneficial, especially considering the autosomal recessive inheritance pattern, as they can provide insights into family planning and genetic testing options. While there are no specific patient organizations identified for AIHA, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable information. Participating in clinical trials may also be an option to consider for accessing new therapies.
Research is ongoing in the field of autoimmune hemolytic anemia, with four orphan drugs currently designated for development. These include a humanized IgG4 monoclonal antibody targeting the complement pathway and a bispecific T cell engager antibody, among others. There are currently 55 active clinical trials exploring various aspects of AIHA treatment and management. For more information on these trials, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=autoimmune%20hemolytic%20anemia.
Actionable guidance for navigating care for autoimmune hemolytic anemia
To navigate your care effectively, seek a hematologist with expertise in autoimmune disorders, particularly those specializing in hemolytic anemias. Engaging with a genetic counselor may also be beneficial, especially considering the autosomal recessive inheritance pattern, as they can provide insights into family planning and genetic testing options. While there are no specific patient organizations identified for AIHA, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable information. Participating in clinical trials may also be an option to consider for accessing new therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 13 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.